Corporate Banner
Satellite Banner
Technology Networks Header
Friday, November 21, 2014
Technology Networks
 
Register | Sign in
Home Page
  About Us

Technology Networks

Established since 2000, Technology Networks is a major online publisher focused on delivering relevant information to the life sciences and drug discovery communities.

In addition to this, our main website, we also produce LabTube - the main scientific video site and ePosters, The Online Journal of Scientific Posters.

Our Communities
Agrigenomics Biologics and Bioprocessing
Biomolecular Screening Cell Culture Chemical Process Scale Up
Chromotography Crystallography Environmental Analysis
Food and Beverage Forensic Science & Clinical Toxicology Gene Silencing
Genomics Genotyping and Gene Expression Immunology
Informatics Lab-on-a-Chip
LIMs and ELNs Market Reports Mass Spectrometry
Medicinal Chemistry Metabolomics and Lipidomics Molecular and Clinical Diagnostics
Next Gen Sequencing PharmaOutsourcing Proteomics
qPCR Spectroscopy Stem Cells, Cellular Therapy & Biobanking

Scientific News
Themis Bioscience’s Vaccine Against Chikungunya Successful in Phase 1
Results presented at international conferences in Philadelphia and New Orleans.
Anti-Leukemia Drug May Also Work Against Ovarian Cancer
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well.
Novel Cancer Vaccine Approach for Brain Tumors
Researchers unravel the mechanisms behind a novel cancer vaccine for brain tumors, paving the way for further development.
Almac Announces Launch of CLIA Validated Next Generation Sequencing Assay
P53 considered important biomarker for cancer drug discovery.
Classification of Gene Mutations in Neuroblastoma
Penn Medicine and CHOP experts define riskier mutations in neuroblastoma, setting stage for clinical trial.
New Vaccine Generates Strong Immune Response Against Hepatitis C
A new hepatitis C vaccine has shown promising results in an early clinical trial at Oxford University, generating strong and broad immune responses against the virus causing the disease.
Immune Booster Helps Improve Survival In Metastatic Melanoma
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant.
Protecting us from Our Cells
Growth factor boosts natural defence against auto-immune disorders.
TxCell Achieves Positive Results for Col-Treg in a Model of Autoimmune Uveitis
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease.
NIH Begins Early Human Clinical Trial of VSV Ebola Vaccine
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health’s Clinical Center in Bethesda, Maryland.
Scroll Up
Scroll Down
SELECTBIO
SELECTBIO Market Reports
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv